Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 55, pages 62–69 (2020)Cite this article

Subjects

Over the last few decades, hematopoietic stem cell transplantation (HSCT) has become an established, life-saving, and a curative treatment option for many indications, including hematological disorders and malignancies, immunodeficiencies, and metabolic disorders, both for adults and children. However, serious complications accompany its use, making HSCT a complex procedure with a dual challenge: curing the underlying disease and preventing relapse, while on the other hand, controlling potentially severe complications [1, 2].

HSCT patients are known to have a very complex pharmacotherapy. Treatment should be undertaken in a specialized unit by a fully dedicated and experienced multidisciplinary team. To ensure safe and effective care and to prevent and solve drug-related problems, a collaboration between clinical pharmacists (CP), clinical pharmacologists (P), and other members of the multidisciplinary team is of paramount importance [3].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. Ther Adv Hematol. 2018;9:123–33. https://doi.org/10.1177/2040620718761776.

    Article  PubMed  PubMed Central  Google Scholar 

  2. McDonald-Hyman C, Turka LA, Blazar BR. Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med. 2015;7:280rv282 https://doi.org/10.1126/scitranslmed.aaa6853.

    Article  Google Scholar 

  3. Bauters T, Vinent-Genestar J, Delaney J, Mycroft J, Vandenbroucke J. Role of the clinical pharmacist in a paediatric haemato-oncology stem cell transplantation ward. Eur J Hosp Pharm. 2014;21:309–12.

    Article  Google Scholar 

  4. Clemmons AB, Alexander M, DeGregory K, Kennedy L. The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group. Biol Blood Marrow Transpl. 2018;24:914–22. https://doi.org/10.1016/j.bbmt.2017.12.803.

    Article  Google Scholar 

  5. Bryk A, Koontz S, Mayor J, Betcher J, Tombleson R, Bookout R et al. Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists. J Oncol Pharm Pract. 2017. https://doi.org/10.1177/1078155217745145

    Article  Google Scholar 

  6. FACT-JACIE International Standards for Hematopoietic Cellular Therapy. In. 7 edn, 2018. https://www.ebmt.org/sites/default/files/2018-06/FACT-JACIE%207th%20Edition%20Standards.pdf. Accessed 14 May 2019.

  7. Yuksel MK, Ilhan O. JACIE: A 20 year-old voluntary body functioning worldwide. Transfus Apher Sci. 2018;57:153–8. https://doi.org/10.1016/j.transci.2018.04.012

    Article  PubMed  Google Scholar 

  8. EBMT Pharmacist Committee. https://www.ebmt.org/pharmacist-committee, accessed 24 April 2019).

  9. Rudis MI, Brandl KM. Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Clinical Pharmacy Task Force on Critical Care Pharmacy Services. Crit Care Med. 2000;28:3746–50.

    Article  CAS  Google Scholar 

  10. Saseen JJ, Ripley TL, Bondi D, Burke JM, Cohen LJ, McBane S, et al. ACCP Clinical Pharmacist Competencies. Pharmacotherapy. 2017;37,:630–6. https://doi.org/10.1002/phar.1923.

    Article  Google Scholar 

  11. Fernandes O, Gorman SK, Slavik RS, Semchuk WM, Shalansky S, Bussieres JF, et al. Development of clinical pharmacy key performance indicators for hospital pharmacists using a modified Delphi approach. Ann Pharm. 2015;49:656–69. https://doi.org/10.1177/1060028015577445.

    Article  Google Scholar 

  12. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282:267–70.

    Article  CAS  Google Scholar 

  13. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007;27:481–93.

    Article  CAS  Google Scholar 

  14. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:735–47.

    Article  CAS  Google Scholar 

  15. Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102:275–80.

    Article  CAS  Google Scholar 

  16. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23:113–32.

    Article  Google Scholar 

  17. Rotta I, Salgado TM, Silva ML, Correr CJ, Fernandez-Llimos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000-2010). Int J Clin Pharm. 2015;37:687–97. https://doi.org/10.1007/s11096-015-0137-9.

    Article  CAS  PubMed  Google Scholar 

  18. Touchette DR, Doloresco F, Suda KJ, Perez A, Turner S, Jalundhwala Y, et al. Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34:771–93. https://doi.org/10.1002/phar.1414.

    Article  PubMed  Google Scholar 

  19. Langebrake C, Ihbe-Heffinger A, Leichenberg K, Kaden S, Kunkel M, Lueb M, et al. Nationwide Evaluation of Day-to-Day Clinical Pharmacists’ Interventions in German Hospitals. Pharmacotherapy. 2015;35:370–9. https://doi.org/10.1002/phar.1578.

    Article  PubMed  Google Scholar 

  20. Langebrake C, Hilgarth H. Clinical pharmacists’ interventions in a German university hospital. Pharm World Sci. 2010;32:194–199. https://doi.org/10.1007/s11096-010-9367-z.

    Article  PubMed  Google Scholar 

  21. FIP Global Conference on the Future of Hospital Pharmacy—Final Basel Statements. 2008. https://www.fip.org/files/fip/HPS/Basel2008/FinalBaselStatements.pdf. Accessed 14 May 2019.

  22. The European Statements of Hospital Pharmacy. Eur J Hosp Pharm. 2014; 21, 256–8. https://ejhp.bmj.com/content/ejhpharm/21/5/256.full.pdf. Accessed 14 May 2019.

  23. Gillaizeau F, Chan E, Trinquart L, Colombet I, Walton R, Rege-Walther M et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2013; 11: CD002894. e-pub ahead of print 2013/11/13; https://doi.org/10.1002/14651858.CD002894.pub3

  24. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526–e536. https://doi.org/10.1016/S2352-3026(16)30114-4.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Andersson BS, Valdez BC. Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? Bone Marrow Transpl. 2016;51:919–20. https://doi.org/10.1038/bmt.2016.110.

    Article  CAS  Google Scholar 

  26. Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4:e183–e191. https://doi.org/10.1016/S2352-3026(17)30029-7.

    Article  PubMed  Google Scholar 

  27. Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et al. Association between anti-thymocyte globulin exposure and CD4+immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194–203. https://doi.org/10.1016/S2352-3026(15)00045-9.

    Article  PubMed  Google Scholar 

  28. Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, et al. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharm. 2015;24:38–44. https://doi.org/10.1016/j.coph.2015.07.002.

    Article  CAS  Google Scholar 

  29. Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-018-0715-9

    Article  Google Scholar 

  30. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, et al. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transpl. 2011;46:20–26. https://doi.org/10.1038/bmt.2010.53.

    Article  CAS  Google Scholar 

  31. Hilken A, Langebrake C, Wolschke C, Kersten JF, Rohde H, Nielsen P et al. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT). Ann Hematol. 2017;96:1379–1388. https://doi.org/10.1007/s00277-017-3034-6.

    Article  CAS  Google Scholar 

  32. Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child. 2014;99:267–72. https://doi.org/10.1136/archdischild-2013-303721.

    Article  PubMed  Google Scholar 

  33. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet. 2016;55:551–93. https://doi.org/10.1007/s40262-015-0340-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. McCune JS, Bemer MJ. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet. 2016;55:525–50. https://doi.org/10.1007/s40262-015-0339-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304. https://doi.org/10.2165/11599410-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  36. Langebrake C, Bernhardt F, Baehr M, Kroger N, Zander AR. Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation. Int J Clin Pharm. 2011;33:918–24. https://doi.org/10.1007/s11096-011-9568-0.

    Article  CAS  PubMed  Google Scholar 

  37. Admiraal R, Boelens JJ. Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy. Expert Opin Biol Ther. 2016;16:801–13. https://doi.org/10.1517/14712598.2016.1164688.

    Article  CAS  PubMed  Google Scholar 

  38. Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2017;109S:S22–S26. https://doi.org/10.1016/j.ejps.2017.05.022.

    Article  Google Scholar 

  39. Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017;35:4003–11. https://doi.org/10.1200/JCO.2017.75.8177.

    Article  CAS  PubMed  Google Scholar 

  40. Ho L, Akada K, Messner H, Kuruvilla J, Wright J, Seki JT. Pharmacist’s Role in Improving Medication Safety for Patients in an Allogeneic Hematopoietic Cell Transplant Ambulatory Clinic. Can J Hosp Pharm. 2013;66:110–7.

    PubMed  PubMed Central  Google Scholar 

  41. Warholak TL, West D, Holdford DA. The Educating Pharmacy Students and Pharmacists to Improve Quality program: tool for pharmacy practice. J Am Pharm Assoc: JAPhA. 2010;50:534–8. https://doi.org/10.1331/JAPhA.2010.10019.

    Article  Google Scholar 

  42. Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transpl. 2018;53:1139–48. https://doi.org/10.1038/s41409-018-0153-1.

    Article  CAS  Google Scholar 

  43. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545–51. https://doi.org/10.1182/blood-2012-05-426783.

    Article  CAS  PubMed  Google Scholar 

  44. Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pr. 2017;6:37–46. https://doi.org/10.2147/IPRP.S108047.

    Article  Google Scholar 

  45. Beck JC, Chen B, Gordon BG. Physician approaches to drug shortages: Results of a national survey of pediatric hematologist/oncologists. World J Clin Oncol. 2017;8:336–42. https://doi.org/10.5306/wjco.v8.i4.336.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Leache L, Aquerreta I, Aldaz A, Idoate A, Ortega A. Evidence of clinical and economic impact of pharmacist interventions related to antimicrobials in the hospital setting. Eur J Clin Microbiol Infect Dis. 2018;37:799–822. https://doi.org/10.1007/s10096-017-3166-6.

    Article  CAS  PubMed  Google Scholar 

  47. Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, Cornely OA, et al. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses. 2017;60:79–88. https://doi.org/10.1111/myc.12552.

    Article  PubMed  Google Scholar 

  48. Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, et al. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis. Bone Marrow Transpl. 2018;53:246–54. https://doi.org/10.1038/s41409-017-0033-0.

    Article  CAS  Google Scholar 

  49. Rubio-Terres C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Lleti M, Toledo A, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis. 2015;34:2213–23. https://doi.org/10.1007/s10096-015-2472-0.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Pharmacy and Department of Stem Cell Transplantation, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

    Claudia Langebrake & Claudia Langebrake

  2. Department of Pediatrics, University Medical Center, Utrecht, The Netherlands

    Rick Admiraal & Rick Admiraal

  3. Pediatric Blood and Marrow Transplant program, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

    Rick Admiraal, Erik van Maarseveen, Rick Admiraal & Erik van Maarseveen

  4. Clinical Pharmacy, University Medical Center, Utrecht, The Netherlands

    Erik van Maarseveen & Erik van Maarseveen

  5. Hematology and Cellular Therapy Department, Saint-Antoine Hospital, Paris, France

    Agnès Bonnin & Agnès Bonnin

  6. Pediatric Hematology/Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

    Tiene Bauters & Tiene Bauters

  7. North East, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

    Anne Black

  8. Portuguese Oncology Institute of Lisbon, Lisbon, Portugal

    Vera Domingos &  Pires

  9. Servicio de Farmacia. Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

    Mª Estela Moreno Martinez

Authors
  1. Claudia Langebrake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rick Admiraal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erik van Maarseveen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Agnès Bonnin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tiene Bauters
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

On behalf of the EBMT Working Group

  • Tiene Bauters
  • , Claudia Langebrake
  • , Rick Admiraal
  • , Erik van Maarseveen
  • , Agnès Bonnin
  • , Anne Black
  • , Vera Domingos
  • ,  Pires
  •  & Mª Estela Moreno Martinez

Corresponding author

Correspondence to Claudia Langebrake.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Members of the EBMT Working Group are listed at the end of the paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Langebrake, C., Admiraal, R., van Maarseveen, E. et al. Consensus recommendations for the role and competencies of the EBMT clinical pharmacist and clinical pharmacologist involved in hematopoietic stem cell transplantation. Bone Marrow Transplant 55, 62–69 (2020). https://doi.org/10.1038/s41409-019-0538-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0538-9

This article is cited by

Search

Advanced search

Quick links